Vertex Pharmaceuticals Incorporated (VRTX) EV/Assets Ratio: 4.10x
Is Vertex Pharmaceuticals Incorporated’s EV/Assets ratio high or low?
Vertex Pharmaceuticals Incorporated's EV/Assets ratio of 4.10x is in line with its 5-year average of 4.46x, near the low end of its 5-year range (3.31x–6.21x).
The EV/Assets ratio for Vertex Pharmaceuticals Incorporated (VRTX) is 4.10x as of Wednesday, June 10, 2026. It is below its 12-month average by 7.85% (4.45x).
VRTX EV/Assets Ratio Chart
VRTX Average EV/Assets Ratio Chart
VRTX Current vs Average EV/Assets Ratio Chart
VRTX EV/Assets Ratio Metrics
EV/ASSETS RATIO
4.10x
EV/ASSETS RATIO AVG TTM
4.45x
EV/ASSETS RATIO AVG 3Y
4.69x
EV/ASSETS RATIO AVG 5Y
4.46x
EV/ASSETS RATIO AVG 10Y
6.37x
EV/ASSETS RATIO AVG 15Y
6.84x
EV/ASSETS RATIO AVG 20Y
6.25x
CURRENT VS TTM AVG
-7.85%
CURRENT VS 3Y AVG
-12.61%
CURRENT VS 5Y AVG
-8.07%
CURRENT VS 10Y AVG
-35.66%
CURRENT VS 15Y AVG
-40.06%
CURRENT VS 20Y AVG
-34.37%
VRTX Competitors' EV/Assets Ratio
| NAME | MARKET CAP | EV/ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Vertex Pharmaceuticals Incorporated (VRTX) | — | 4.10x | 4.45x | 4.69x | 4.46x |
| Bristol-Myers Squibb Company (BMY) | $114.14B | 1.72x | 1.55x | 1.56x | 1.64x |
| Medtronic plc (MDT) | $103.04B | 1.42x | 1.59x | 1.53x | 1.60x |
| CVS Health Corporation (CVS) | $125.16B | 0.77x | 0.67x | 0.63x | 0.70x |
| Danaher Corporation (DHR) | $130.25B | 1.72x | 1.98x | 2.16x | 2.26x |
| Elevance Health Inc. (ELV) | $87.43B | 0.88x | 0.80x | 1.03x | 1.13x |
| Cigna Corporation (CI) | $78.25B | 0.67x | 0.66x | 0.72x | 0.73x |
| Pfizer Inc. (PFE) | $146.36B | 1.01x | 1.00x | 1.03x | 1.28x |
| Intuitive Surgical, Inc. (ISRG) | $146.44B | 7.30x | 8.88x | 9.09x | 8.50x |
| Gilead Sciences, Inc. (GILD) | $151.21B | 2.97x | 3.05x | 2.44x | 2.15x |
Vertex Pharmaceuticals Incorporated EV/Assets Ratio Formula & Definition
EV/Assets compares enterprise value to total assets. It is useful for asset-heavy businesses and for comparing how much the market pays for each dollar of assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Vertex Pharmaceuticals Incorporated EV/Assets Ratio FAQ
- What is the EV/Assets ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
- The EV/Assets ratio for VRTX stock is 4.10x.
- Is Vertex Pharmaceuticals Incorporated's EV/Assets ratio high or low?
- Vertex Pharmaceuticals Incorporated's EV/Assets ratio of 4.10x is in line with its 5-year average of 4.46x, near the low end of its 5-year range (3.31x–6.21x).
- What is the TTM average EV/Assets ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
- The TTM average EV/Assets ratio for VRTX stock is 4.45x.
- What is the 3Y average EV/Assets ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 3Y average EV/Assets ratio for VRTX stock is 4.69x.
- What is the 5Y average EV/Assets ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 5Y average EV/Assets ratio for VRTX stock is 4.46x.
- What is the 10Y average EV/Assets ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 10Y average EV/Assets ratio for VRTX stock is 6.37x.
- What is the 15Y average EV/Assets ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 15Y average EV/Assets ratio for VRTX stock is 6.84x.
- What is the 20Y average EV/Assets ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 20Y average EV/Assets ratio for VRTX stock is 6.25x.
Vertex Pharmaceuticals Incorporated EV/Assets Ratio History
| DATE | EV/ASSETS RATIO |
|---|---|
| 2026-06-10 | 4.10x |
| 2026-06-09 | 4.18x |
| 2026-06-08 | 4.15x |
| 2026-06-05 | 4.19x |
| 2026-06-04 | 4.14x |
| 2026-06-03 | 4.01x |
| 2026-06-02 | 3.98x |
| 2026-06-01 | 4.11x |
| 2026-05-29 | 4.20x |
| 2026-05-28 | 4.20x |
| 2026-05-27 | 4.10x |
| 2026-05-26 | 4.09x |
| 2026-05-22 | 4.07x |
| 2026-05-21 | 4.06x |
| 2026-05-20 | 4.03x |
| 2026-05-19 | 4.07x |
| 2026-05-18 | 4.09x |
| 2026-05-15 | 4.10x |
| 2026-05-14 | 4.23x |
| 2026-05-13 | 4.25x |
| 2026-05-12 | 4.21x |
| 2026-05-11 | 4.08x |
| 2026-05-08 | 4.03x |
| 2026-05-07 | 3.98x |
| 2026-05-06 | 4.01x |
| 2026-05-05 | 3.97x |
| 2026-05-04 | 4.16x |
| 2026-05-01 | 4.11x |
| 2026-04-30 | 4.14x |
| 2026-04-29 | 4.10x |
| 2026-04-28 | 4.17x |
| 2026-04-27 | 4.13x |
| 2026-04-24 | 4.17x |
| 2026-04-23 | 4.22x |
| 2026-04-22 | 4.24x |
| 2026-04-21 | 4.23x |
| 2026-04-20 | 4.26x |
| 2026-04-17 | 4.28x |
| 2026-04-16 | 4.22x |
| 2026-04-15 | 4.28x |
| 2026-04-14 | 4.31x |
| 2026-04-13 | 4.26x |
| 2026-04-10 | 4.23x |
| 2026-04-09 | 4.33x |
| 2026-04-08 | 4.30x |
| 2026-04-07 | 4.18x |
| 2026-04-06 | 4.21x |
| 2026-04-02 | 4.25x |
| 2026-04-01 | 4.34x |
| 2026-03-31 | 4.33x |
| 2026-03-30 | 4.30x |
| 2026-03-27 | 4.20x |
| 2026-03-26 | 4.40x |
| 2026-03-25 | 4.41x |
| 2026-03-24 | 4.35x |
| 2026-03-23 | 4.37x |
| 2026-03-20 | 4.40x |
| 2026-03-19 | 4.44x |
| 2026-03-18 | 4.38x |
| 2026-03-17 | 4.48x |
| 2026-03-16 | 4.52x |
| 2026-03-13 | 4.55x |
| 2026-03-12 | 4.64x |
| 2026-03-11 | 4.78x |
| 2026-03-10 | 4.84x |
| 2026-03-09 | 4.47x |
| 2026-03-06 | 4.43x |
| 2026-03-05 | 4.47x |
| 2026-03-04 | 4.64x |
| 2026-03-03 | 4.60x |
| 2026-03-02 | 4.72x |
| 2026-02-27 | 4.82x |
| 2026-02-26 | 4.66x |
| 2026-02-25 | 4.69x |
| 2026-02-24 | 4.73x |
| 2026-02-23 | 4.67x |
| 2026-02-20 | 4.63x |
| 2026-02-19 | 4.55x |
| 2026-02-18 | 4.56x |
| 2026-02-17 | 4.63x |
| 2026-02-13 | 4.77x |
| 2026-02-12 | 4.69x |
| 2026-02-11 | 4.65x |
| 2026-02-10 | 4.68x |
| 2026-02-09 | 4.75x |
| 2026-02-06 | 4.83x |
| 2026-02-05 | 4.63x |
| 2026-02-04 | 4.75x |
| 2026-02-03 | 4.70x |
| 2026-02-02 | 4.77x |
| 2026-01-30 | 4.74x |
| 2026-01-29 | 4.80x |
| 2026-01-28 | 4.83x |
| 2026-01-27 | 4.79x |
| 2026-01-26 | 4.82x |
| 2026-01-23 | 4.73x |
| 2026-01-22 | 4.72x |
| 2026-01-21 | 4.65x |
| 2026-01-20 | 4.46x |
| 2026-01-16 | 4.45x |
| 2026-01-15 | 4.42x |
| 2026-01-14 | 4.53x |
| 2026-01-13 | 4.59x |
| 2026-01-12 | 4.65x |
| 2026-01-09 | 4.68x |
| 2026-01-08 | 4.74x |
| 2026-01-07 | 4.89x |
| 2026-01-06 | 4.73x |
| 2026-01-05 | 4.53x |
| 2026-01-02 | 4.56x |
| 2025-12-31 | 4.57x |
| 2025-12-30 | 4.58x |
| 2025-12-29 | 4.64x |
| 2025-12-26 | 4.67x |
| 2025-12-24 | 4.67x |
| 2025-12-23 | 4.63x |
| 2025-12-22 | 4.64x |
| 2025-12-19 | 4.60x |
| 2025-12-18 | 4.51x |
| 2025-12-17 | 4.53x |
| 2025-12-16 | 4.59x |
| 2025-12-15 | 4.60x |
| 2025-12-12 | 4.56x |
| 2025-12-11 | 4.50x |
| 2025-12-10 | 4.48x |
| 2025-12-09 | 4.40x |
| 2025-12-08 | 4.46x |
| 2025-12-05 | 4.59x |
| 2025-12-04 | 4.61x |
| 2025-12-03 | 4.67x |
| 2025-12-02 | 4.36x |
| 2025-12-01 | 4.28x |
| 2025-11-28 | 4.37x |
| 2025-11-26 | 4.35x |
| 2025-11-25 | 4.33x |
| 2025-11-24 | 4.27x |
| 2025-11-21 | 4.30x |
| 2025-11-20 | 4.25x |
| 2025-11-19 | 4.24x |
| 2025-11-18 | 4.39x |
| 2025-11-17 | 4.37x |
| 2025-11-14 | 4.40x |
| 2025-11-13 | 4.38x |
| 2025-11-12 | 4.37x |
| 2025-11-11 | 4.32x |
| 2025-11-10 | 4.24x |
| 2025-11-07 | 4.12x |
| 2025-11-06 | 4.19x |
| 2025-11-05 | 4.20x |
| 2025-11-04 | 4.24x |
| 2025-11-03 | 4.45x |
| 2025-10-31 | 4.44x |
| 2025-10-30 | 4.38x |
| 2025-10-29 | 4.35x |
| 2025-10-28 | 4.41x |
| 2025-10-27 | 4.38x |
| 2025-10-24 | 4.40x |
| 2025-10-23 | 4.41x |
| 2025-10-22 | 4.45x |
| 2025-10-21 | 4.45x |
| 2025-10-20 | 4.37x |
| 2025-10-17 | 4.35x |
| 2025-10-16 | 4.26x |
| 2025-10-15 | 4.25x |
| 2025-10-14 | 4.30x |
| 2025-10-13 | 4.24x |
| 2025-10-10 | 4.25x |
| 2025-10-09 | 4.33x |
| 2025-10-08 | 4.39x |
| 2025-10-07 | 4.28x |
| 2025-10-06 | 4.20x |
| 2025-10-03 | 4.20x |
| 2025-10-02 | 4.26x |
| 2025-10-01 | 4.21x |
| 2025-09-30 | 4.08x |
| 2025-09-29 | 4.11x |
| 2025-09-26 | 4.01x |
| 2025-09-25 | 3.97x |
| 2025-09-24 | 3.91x |
| 2025-09-23 | 3.95x |
| 2025-09-22 | 3.98x |
| 2025-09-19 | 3.98x |
| 2025-09-18 | 4.03x |
| 2025-09-17 | 4.03x |
| 2025-09-16 | 4.07x |
| 2025-09-15 | 4.09x |
| 2025-09-12 | 4.11x |
| 2025-09-11 | 4.14x |
| 2025-09-10 | 4.04x |
| 2025-09-09 | 4.13x |
| 2025-09-08 | 4.11x |
| 2025-09-05 | 4.12x |
| 2025-09-04 | 4.13x |
| 2025-09-03 | 4.13x |
| 2025-09-02 | 4.18x |
| 2025-08-29 | 4.07x |
| 2025-08-28 | 4.08x |
| 2025-08-27 | 4.05x |
| 2025-08-26 | 4.03x |
| 2025-08-25 | 4.05x |
| 2025-08-22 | 4.11x |
| 2025-08-21 | 4.14x |
| 2025-08-20 | 4.10x |
| 2025-08-19 | 4.07x |
| 2025-08-18 | 4.06x |
| 2025-08-15 | 4.09x |
| 2025-08-14 | 4.06x |
| 2025-08-13 | 4.12x |
| 2025-08-12 | 4.03x |
| 2025-08-11 | 3.89x |
| 2025-08-08 | 3.80x |
| 2025-08-07 | 3.90x |
| 2025-08-06 | 4.01x |
| 2025-08-05 | 3.90x |
| 2025-08-04 | 5.22x |
| 2025-08-01 | 5.11x |
| 2025-07-31 | 5.05x |
| 2025-07-30 | 5.19x |
| 2025-07-29 | 5.18x |
| 2025-07-28 | 5.09x |
| 2025-07-25 | 5.19x |
| 2025-07-24 | 5.22x |
| 2025-07-23 | 5.28x |
| 2025-07-22 | 5.20x |
| 2025-07-21 | 5.07x |
| 2025-07-18 | 5.08x |
| 2025-07-17 | 5.12x |
| 2025-07-16 | 5.19x |
| 2025-07-15 | 5.13x |
| 2025-07-14 | 5.22x |
| 2025-07-11 | 5.19x |
| 2025-07-10 | 5.31x |
| 2025-07-09 | 5.30x |
| 2025-07-08 | 5.16x |
| 2025-07-07 | 5.08x |
| 2025-07-03 | 5.08x |
| 2025-07-02 | 5.05x |
| 2025-07-01 | 5.00x |
| 2025-06-30 | 4.92x |
| 2025-06-27 | 4.87x |
| 2025-06-26 | 4.90x |
| 2025-06-25 | 4.92x |
| 2025-06-24 | 4.97x |
| 2025-06-23 | 4.90x |
| 2025-06-20 | 4.87x |
| 2025-06-18 | 4.95x |
| 2025-06-17 | 4.88x |
| 2025-06-16 | 4.98x |
| 2025-06-13 | 5.03x |
| 2025-06-12 | 5.09x |
| 2025-06-11 | 5.00x |
| 2025-06-10 | 4.99x |
| 2025-06-09 | 4.93x |
| 2025-06-06 | 4.98x |
| 2025-06-05 | 4.90x |
| 2025-06-04 | 4.92x |
| 2025-06-03 | 4.93x |
| 2025-06-02 | 4.92x |
| 2025-05-30 | 4.88x |
| 2025-05-29 | 4.94x |
Showing the most recent 260 of 5,031 data points. The chart above shows the full history.
Related Metrics
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Reshma Kewalramani